Comparison of the incidence and duration of hypoglycaemia assessed by Continuous Glucose Monitoring (CGM) in patients aged 65 years or older with Type 2 Diabetes (T2D), treated with Insulin Glargine (Toujeo) and Insulin Glulisine (Apidra) Versus Twice Daily Premixed Insulin.

Trial Profile

Comparison of the incidence and duration of hypoglycaemia assessed by Continuous Glucose Monitoring (CGM) in patients aged 65 years or older with Type 2 Diabetes (T2D), treated with Insulin Glargine (Toujeo) and Insulin Glulisine (Apidra) Versus Twice Daily Premixed Insulin.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2017

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin glulisine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CHAMPION
  • Most Recent Events

    • 18 Dec 2017 Planned End Date changed from 21 Oct 2018 to 31 Mar 2020.
    • 18 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 21 Nov 2016 Planned End Date changed from 30 Nov 2017 to 21 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top